Literature DB >> 22512631

Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy.

Steven Eric Finkelstein1, Francisco Rodriguez, Mary Dunn, Mary-Jane Farmello, Renee Smilee, William Janssen, Loveleen Kang, Tian Chuang, John Seigne, Julio Pow-Sang, Javier F Torres-Roca, Randy Heysek, Matt Biagoli, Ravi Shankar, Jacob Scott, Scott Antonia, Dmitry Gabrilovich, Mayer Fishman.   

Abstract

Local radiotherapy plus intratumoral syngeneic dendritic cell injection can mediate apoptosis/cell death and immunological tumor eradication in murine models. A novel method of coordinated intraprostatic, autologous dendritic cell injection together with radiation therapy was prospectively evaluated in five HLA-A2(+) subjects with high-risk, localized prostate cancer, using androgen suppression, 45 Gy external beam radiation therapy in 25 fractions over 5 weeks, dendritic cell injections after fractions 5, 15 and 25 and then interstitial radioactive seed placement. Serial prostate biopsies before and during treatment showed increased apoptotic cells and parenchymal distribution of CD8(+) cells. CD8(+) T-cell responses to test peptides were assessed using an enzyme-linked immunosorbent spot IFN-γ production assay, demonstrating some prostate cancer-specific protein-derived peptides associated with increased titer. In conclusion, the technique was feasible and well-tolerated and specific immune responses were observable. Future trials could further test the utility of this approach and improve on temporal coordination of intratumoral dendritic cell introduction with particular timelines of therapy-induced apoptosis.

Entities:  

Mesh:

Year:  2012        PMID: 22512631      PMCID: PMC4241355          DOI: 10.2217/imt.12.24

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  24 in total

Review 1.  Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer.

Authors:  Rupal Ramakrishnan; Dmitry I Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2010-10-26       Impact factor: 6.968

Review 2.  Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.

Authors:  P Milecki; Z Kwias; D J J Martenka
Journal:  Neoplasma       Date:  2007       Impact factor: 2.575

3.  Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients.

Authors:  Tetsuo Fujita; Bin S Teh; Terry L Timme; Wei-Yuan Mai; Takefumi Satoh; Nobuyuki Kusaka; Koji Naruishi; Elmoataz Abdel Fattah; Estuardo Aguilar-Cordova; E Brian Butler; Timothy C Thompson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-02-10       Impact factor: 7.038

4.  Influences of surgical castration on the thymus of male rats.

Authors:  K F Windmill; V W Lee
Journal:  J Reprod Immunol       Date:  1999-09       Impact factor: 4.054

5.  Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

Authors:  James L Gulley; Philip M Arlen; Anne Bastian; Steven Morin; Jennifer Marte; Patricia Beetham; Kwong-Yok Tsang; Junko Yokokawa; James W Hodge; Cynthia Ménard; Kevin Camphausen; C Norman Coleman; Francis Sullivan; Seth M Steinberg; Jeffrey Schlom; William Dahut
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

Review 6.  Combining radiotherapy and immunotherapy: a revived partnership.

Authors:  Sandra Demaria; Nina Bhardwaj; William H McBride; Silvia C Formenti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-01       Impact factor: 7.038

7.  Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients.

Authors:  Steven E Finkelstein; Cristina Iclozan; Marilyn M Bui; Matthew J Cotter; Rupal Ramakrishnan; Jamil Ahmed; David R Noyes; David Cheong; Ricardo J Gonzalez; Randy V Heysek; Claudia Berman; Brianna C Lenox; William Janssen; Jonathan S Zager; Vernon K Sondak; G Douglas Letson; Scott J Antonia; Dmitry I Gabrilovich
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-03-11       Impact factor: 7.038

8.  HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.

Authors:  Cesar A Corzo; Thomas Condamine; Lily Lu; Matthew J Cotter; Je-In Youn; Pingyan Cheng; Hyun-Il Cho; Esteban Celis; David G Quiceno; Tapan Padhya; Thomas V McCaffrey; Judith C McCaffrey; Dmitry I Gabrilovich
Journal:  J Exp Med       Date:  2010-09-27       Impact factor: 14.307

9.  Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells.

Authors:  Yulia Nefedova; Mayer Fishman; Simon Sherman; Xingyu Wang; Amer A Beg; Dmitry I Gabrilovich
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

Review 10.  The confluence of stereotactic ablative radiotherapy and tumor immunology.

Authors:  Steven Eric Finkelstein; Robert Timmerman; William H McBride; Dörthe Schaue; Sarah E Hoffe; Constantine A Mantz; George D Wilson
Journal:  Clin Dev Immunol       Date:  2011-11-15
View more
  15 in total

1.  Impact of curative radiotherapy on the immune status of patients with localized prostate cancer.

Authors:  Franziska Eckert; Philipp Schaedle; Daniel Zips; Barbara Schmid-Horch; Hans-Georg Rammensee; Cihan Gani; Cécile Gouttefangeas
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

Review 2.  Personalized peptide vaccines and their relation to other therapies in urological cancer.

Authors:  Takahiro Kimura; Shin Egawa; Hirotsugu Uemura
Journal:  Nat Rev Urol       Date:  2017-05-31       Impact factor: 14.432

3.  Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer.

Authors:  Lindsay K Ward-Kavanagh; Junjia Zhu; Timothy K Cooper; Todd D Schell
Journal:  Cancer Immunol Res       Date:  2014-05-06       Impact factor: 11.151

Review 4.  Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors.

Authors:  Eric D Brooks; Jonathan E Schoenhals; Chad Tang; Goran Micevic; Daniel R Gomez; Joe Y Chang; James W Welsh
Journal:  Cancer J       Date:  2016 Jul-Aug       Impact factor: 3.360

5.  Clinical opportunities in combining immunotherapy with radiation therapy.

Authors:  Steven E Finkelstein; Mayer Fishman
Journal:  Front Oncol       Date:  2012-11-26       Impact factor: 6.244

Review 6.  Combinations of immunotherapy and radiation in cancer therapy.

Authors:  Ralph E Vatner; Benjamin T Cooper; Claire Vanpouille-Box; Sandra Demaria; Silvia C Formenti
Journal:  Front Oncol       Date:  2014-11-28       Impact factor: 6.244

7.  Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival.

Authors:  Jan Poleszczuk; Kimberly Luddy; Lu Chen; Jae K Lee; Louis B Harrison; Brian J Czerniecki; Hatem Soliman; Heiko Enderling
Journal:  Breast Cancer Res       Date:  2017-06-30       Impact factor: 6.466

Review 8.  Harnessing the potential of multimodal radiotherapy in prostate cancer.

Authors:  Yiannis Philippou; Hanna Sjoberg; Alastair D Lamb; Philip Camilleri; Richard J Bryant
Journal:  Nat Rev Urol       Date:  2020-05-01       Impact factor: 14.432

9.  Immune-maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity-modulated radiation.

Authors:  Yuta Shibamoto; Masato Okamoto; Masanori Kobayashi; Shiho Ayakawa; Hiromitsu Iwata; Chikao Sugie; Yoko Mitsuishi; Hidenori Takahashi
Journal:  Mol Clin Oncol       Date:  2013-04-26

10.  Current clinical trials testing the combination of immunotherapy with radiotherapy.

Authors:  Josephine Kang; Sandra Demaria; Silvia Formenti
Journal:  J Immunother Cancer       Date:  2016-09-20       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.